Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Medtech venture capital has not simply disappeared; the evidence points to a more selective, concentrated market. In Q1 2026, reported venture deal value fell faster than deal count, while median deal size and exits rose. That mix suggests money is reaching fewer or larger deals even as fundraising remains difficult for many companies. It does not prove the market has turned around, and the available figures cover different periods and definitions of medtech.
What the Q1 numbers say—and what they do not
MedCity News contributor Jordan Lisnow reported PitchBook figures showing that medtech VC deal value fell 17.1% year over year in Q1 2026, while deal count fell 3.7%. The median deal size was $11.8 million, up from $10 million for 2025. These are not contradictory signals: total dollars can decline while the median rises if fewer deals close, or if capital is concentrated in larger rounds.
The higher median does not establish that the typical startup found it easier to raise. It says nothing on its own about how many companies sought funding, how many failed to secure it, or how the rounds were distributed by stage. The underlying PitchBook report linked from Lisnow’s article was inaccessible, so these figures should be understood as PitchBook data relayed by the author, not as independently checked figures. MedCity News, October 6, 2026.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteLisnow also reported $4.1 billion in medtech VC exits in Q1 2026, nearly half of the 2025 total, citing EdgeMedical’s $2.2 billion surgical-robotics IPO as an anchor. That exit total is attributed to the article; the available evidence does not independently establish its underlying calculation. Exits can occur while new fundraising remains constrained, so exit activity is not a direct measure of how accessible capital is to startups.
#1 Best Overall
Keep private equity separate from venture capital
The same article reports that medtech private-equity deal count fell about 41% year over year to 26 deals in Q1. This is a private-equity statistic, not a venture deal count, and should not be folded into the VC decline figures.
Why the half-year view looks less bleak
HSBC Innovation Banking’s 1H 2026 med-device summary describes investment as slightly below 2025’s record pace but above activity in 2023 and 2024. It also reports a sharp rise in first financings, led by larger Series A rounds. That broader half-year view does not cancel out Q1’s year-over-year VC declines: it covers a different time window and uses its own med-device categories. HSBC Innovation Banking’s 1H 2026 report.
HSBC reports 24 med-device financings of at least $50 million in 1H 2026, including large financings in neuro and brain-computer-interface technologies. In the same period, it counted twelve venture-backed M&A deals, with a median upfront payment of $345 million. It also reported six IPOs over 18 months and a median post-IPO performance of +4%. Those are HSBC’s reported measures and periods; M&A, IPO performance and venture funding describe different parts of the market.
Investment patterns vary by category
HSBC says investment increased in neuro, imaging and non-invasive monitoring in 1H 2026, while cardiovascular investment pulled back. PwC, looking at strategic dealmaking rather than venture financings, describes continuing buyer interest in cardiovascular, neurostimulation, connected care and workflow platforms. These findings are not a single ranking of the “hottest” areas: one tracks venture investment and the other strategic M&A interest.
What strategic dealmaking adds to the picture
PwC US reported $36.5 billion in US medtech deal value in 1H 2026. This is M&A deal value, not VC financing. PwC describes active M&A and ongoing strategic interest in differentiated technologies, while saying startup VC funding remains constrained and IPO reopening is inconsistent. Its June 17, 2026 article frames buyers’ priorities as durable growth, differentiated technologies and long-term category leadership. PwC US’s medtech dealmaking outlook.
Read alongside the financing data, this points to a market where strategic buyers may still pursue specific assets even when the path to venture funding or an IPO is uneven. It does not mean every startup has a likely buyer, or that acquisition interest translates into accessible early-stage capital.
Does AI explain the pressure on medtech funding?
Lisnow’s thesis is that AI’s share of US venture dollars, LP liquidity constraints and difficulty raising specialist funds are contributing to competition for medtech capital. The article attributes its AI and fund-commitment figures to PitchBook, but the linked underlying page was inaccessible. Treat the explanation as the author’s interpretation of the market, not a measured causal finding: the available figures do not isolate how much of medtech’s Q1 decline was caused by AI, LP liquidity or any other factor.
The same article identifies Medtronic Ventures, Johnson & Johnson’s JJDC and Philips Ventures as corporate investors increasing early-stage activity. PwC separately describes corporate venture investment and strategic partnerships as important to maintaining innovation pipelines while traditional funding and IPO routes are constrained. Corporate participation is one channel in the market, not proof that the broader funding squeeze has ended.
Best Value
What founders can take from this market
For founders, the most defensible takeaway is not that funding is gone, but that a company needs to make its case clearly. Lisnow describes clinical validation, a clear regulatory pathway and real hospital demand as the price of entry. HTD Health’s December 2025 outlook adds interoperability, security, reimbursement visibility and commercial viability as investor diligence themes. These are attributed observations, not universal requirements that apply identically to every company, stage or device. HTD Health’s 2026 outlook.
- Clinical evidence: Explain what has been validated, in which population or setting, and what evidence remains to be generated.
- Regulatory route: Describe the intended pathway and the milestones, time and resources needed to reach it.
- Customer demand: Show credible interest from hospitals or other intended buyers, rather than relying on a broad claim about market size.
- Implementation and economics: Address interoperability, security, reimbursement and the commercial case for adoption.
- Differentiation: Make clear why the technology is meaningfully distinct and valuable to customers or strategic partners.
This checklist cannot guarantee a round. It helps make the risks and milestones legible to investors in a market where the headline data suggest capital is being deployed more selectively.
How to read claims that medtech VC is “in decline”
Before treating any market statistic as a verdict, check what it measures. Q1 venture deal value is not the same as deal count; a median round size is not a measure of fundraising success; private-equity activity is not venture activity; and exits or M&A do not equal new startup financing. The Q1 figures attributed to PitchBook, HSBC’s 1H med-device summary and PwC’s 1H M&A total cannot be combined into one continuous dataset.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →The evidence supports a qualified answer: Q1 venture value declined, but deal count declined much less, the reported median round was larger, and exits were substantial. HSBC’s half-year view shows med-device investment below the 2025 record but above 2023 and 2024. Taken together, those indicators fit a selective and concentrated market better than a simple story of medtech VC being dead. They do not settle whether the pullback is temporary or a lasting repricing.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
